Cannabidiol for self-injury in children with severe developmental disorders
Treatments studied
Part of Mental health clinical trials.
This trial tests whether a medication called cannabidiol (a cannabis-derived compound) can reduce severe self-injury behaviors in children and teens with severe neurodevelopmental disorders. It aims to see if it's safe and effective when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 5 and 17.5 years old and weigh between 12 and 49.9 kg (about 26 to 110 pounds).
- You must have a severe neurodevelopmental disorder that requires help with daily activities and constant supervision.
- You must have had severe self-injuries in the last 7 days, like hitting or biting yourself, that happen often.
- Standard medications for self-injury (like risperidone or aripiprazole) have not worked for at least 30 days.
- Your other treatments (like therapy or medications) have not changed in the last month.
- A caregiver must be able to bring you to all visits and help with the study.
- Both parents or legal guardians must agree to the study.
- You must not be taking certain medications that interact with the study drug, and must not have epilepsy or a history of epilepsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to cannabidiol (CBD), a marijuana-derived compound, for children with severe epilepsy that hasn't improved with standard medications. The goal is to see if CBD can help reduce seizures in this difficult-to-treat group.
This study looks at how to reduce serious problem behaviors (including self-injury) in children who have it many times per day even after previous treatment. It may help if your child’s behavior is driven by social attention or other positive effects and they can stay on the same supports, school plan, and medicines during the study.
This study tests whether a medication called cannabidiol (a non-intoxicating compound from cannabis) can help reduce symptoms and prevent progression in young people at clinical high risk for psychosis. Participants will receive either the study drug or a placebo (a pill with no active ingredient) and will be followed to see how they respond.
This trial tests a new cell-based treatment (called VGN-Ex05e) for young people with autism who have severe self-injury or aggression that hasn't improved with standard treatments. The treatment is given as a one-time injection into a specific area of the brain (nucleus accumbens) to help calm these behaviors.
This study tests whether deep brain stimulation can reduce severe self-injurious behaviors in children with autism. If standard treatments haven't worked, this approach may offer a new option.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
Hear when a new Neurodevelopmental Disorders With Severe Self-injuries trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.